diABZI STING agonist-1 3HCl is a selective STING agonist with EC50 values of 130 and 186 nM in humans and mice, respectively. diABZI STING agonist-1 3HCl is highly selective for more than 350 kinases at a concentration of 1 μM[1].
diABZI STING agonist-1 3HCl 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Female BALB/cJ mice
Skin inflammation model
Subcutaneous injection
2.5 mg/kg
Single injection, monitored for up to 6 weeks
To investigate the role of STING activation in skin inflammation, results showed that diABZI injection induced severe skin inflammation including erythema, scaling, and induration, which resolved within 6 weeks.
Int J Mol Sci. 2023 Feb 18;24(4):4128
diABZI STING agonist-1 3HCl 动物研究
Animal study
Administered intravenously at a dose of 3 mg/kg, diABZI STING agonist-1 3HCl demonstrated a systemic exposure half-life of 1.4 hours and achieved systemic concentrations higher than the EC50 for mouse STING (200 ng/ml). Administered subcutaneously at a dose of 2.5 mg/kg, diABZI STING agonist-1 3HCl induced STING-dependent activation of type I interferons and pro-inflammatory cytokines in in vivo experiments. In the BALB/c mouse colorectal tumour homozygous mouse model (CT-26), diABZI STING agonist-1 3HCl, administered intravenously at a dose of 1.5 mg/kg, significantly inhibited tumour growth and significantly increased animal survival. At the end of the study on day 43, 8 out of 10 mice remained tumour free[1].
搜索
